Join the Respiratory Syncytial Virus group to help and get support from people like you.
Respiratory Syncytial Virus News
Related terms: Bronchiolitis, RSV
RSV Vaccine Prevents RSV-Linked Hospitalization Among Older Adults Over Two Seasons
FRIDAY, Sept. 12, 2025 – The respiratory syncytial virus (RSV) vaccine reduces RSV-associated hospitalization among older adults over two seasons, according to a study published online Sept. 3 in...
Infants Without Comorbidities Also at Risk for Severe RSV Infection
THURSDAY, Sept. 11, 2025 – Comorbidities are seen less often in severe respiratory syncytial virus (RSV) infection in infants younger than 3 months compared with older children, according to a study...
Even Healthy Babies At Risk For Severe RSV Infection
FRIDAY, Sept. 12, 2025 — RSV can make even healthy, full-term babies sick enough to land in the hospital or require intensive care, a new study says. In fact, more than half of RSV-infected infants a...
One Dose of RSV Vaccine May Shield Older People for Two Seasons
WEDNESDAY, Sept. 3, 2025 — A single dose of RSV vaccine might protect seniors for two cold and flu seasons in a row, a new study says. Vaccination reduced seniors’ risk of hospitalization by 58% dur...
Heart Patients Urged To Seek Vaccination For Common Infectious Diseases
WEDNESDAY, Aug. 27, 2025 — It is vital that people with heart disease get vaccinated against common infectious diseases like COVID-19, influenza and RSV, a new clinical guideline says. Vaccination c...
29 Percent of Infants Immunized Against RSV in 2023 to 2024 Season
MONDAY, Aug. 25, 2025 – Overall, 29 percent of infants born during October 2023 to March 2024 were immunized against respiratory syncytial virus (RSV) during the 2023 to 2024 respiratory virus...
Nearly 9 in 10 ER Patients Aren't Fully Vaccinated
MONDAY, Aug. 11, 2025 — Nearly 9 out of 10 adults who land in an ER haven't been fully vaccinated, a new study says. People who came to an emergency department for treatment of minor injuries or i...
Nirsevimab Effective for Protecting Infants From RSV Lower Respiratory Tract Disease
WEDNESDAY, July 30, 2025 – Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD), according to a study published...
Seniors With RSV-Linked Hospitalization Have Increased Cardiovascular Outcomes
THURSDAY, July 24, 2025 – In older adults, respiratory syncytial virus (RSV) is associated with an increased risk for cardiovascular outcome, especially heart failure events, according to a study...
35 Percent of Eligible Children Receive RSV Prophylaxis With Nirsevimab
TUESDAY, July 22, 2025 – Despite near universal availability of nirsevimab, only 35 percent of eligible children receive nirsevimab for respiratory syncytial virus (RSV) prophylaxis, according to a...
Few Babies Getting RSV Antibody Shot, Beyfortus, Study Says
THURSDAY, July 17, 2025 — A new antibody shot that protects babies against RSV infection could be struggling to gain traction, researchers report. Only about a third (35%) of babies eligible for n...
CDC Now Recommends RSV Vaccine for Some Adults 50+
MONDAY, July 7, 2025 — Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update from the U.S. Centers for Disease Control and P...
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), the Company's...
New Antibody Shot, Enflonsia, Could Help Protect Babies From RSV
THURSDAY, June 12, 2025 — A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in U.S. infants. The U.S. Food and Drug A...
RSV Vaccines, Nirsevimab Tied to Reduced RSV-Linked Hospitalization
TUESDAY, May 13, 2025 – Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated hospitalization rates among infants aged 0 to 7...